NCT06547008 Army-SPRING Army-Suicide Prevention Research
| NCT ID | NCT06547008 |
| Status | Recruiting |
| Phase | Phase 1 |
| Sponsor | University of Pennsylvania |
| Condition | Suicide |
| Study Type | INTERVENTIONAL |
| Enrollment | 57 participants |
| Start Date | 2025-03-19 |
| Primary Completion | 2027-09 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 57 participants in total. It began in 2025-03-19 with a primary completion date of 2027-09.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Every unit in the Connecticut Army National Guard has a Suicide Intervention Officer to provide suicide intervention education awareness for their unit, monitor for soldiers in crisis and connect soldiers with helping resources and agencies. Suicide Intervention Officers need support in this difficult role, yet there is limited guidance on how to help them. This study will shed light on how to support Suicide Intervention Officers and whether this support results in reduced suicide risk in their units.
Eligibility Criteria
Inclusion Criteria: * Serving as an SIO or chaplain/religious affairs specialist for a unit of the CTARNG * Willing to provide informed consent. Exclusion Criteria: * None
Contact & Investigator
Lily Brown, PhD
PRINCIPAL INVESTIGATOR
University of Pennsylvania
Frequently Asked Questions
Who can join the NCT06547008 clinical trial?
This trial is open to participants of all sexes, studying Suicide. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06547008 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT06547008 currently recruiting?
Yes, NCT06547008 is actively recruiting participants. Contact the research team at lilybr@pennmedicine.upenn.edu for enrollment information.
Where is the NCT06547008 trial being conducted?
This trial is being conducted at Hartford, United States, New Haven, United States, Philadelphia, United States.
Who is sponsoring the NCT06547008 clinical trial?
NCT06547008 is sponsored by University of Pennsylvania. The principal investigator is Lily Brown, PhD at University of Pennsylvania. The trial plans to enroll 57 participants.